CORPORATE ACCESS

A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.

Your Search Niagen News

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Oct 2, 2023 | ,

Celebrating a significant achievement in NAD+ research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders LOS ANGELES...

read more

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Aug 24, 2023 | ,

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide...

read more

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Jul 18, 2023 | ,

Abstracts recently published in the Association for Research in Vision and Ophthalmology (ARVO) journal showcase NR, one of the most efficient and well-researched NAD+ precursors, prevented the worsening of visual field sensitivity in glaucoma patients, and builds on...

read more

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Jun 16, 2023 | ,

Through CERP™, over 275 global research agreements with 235+ independent, expert investigators are uncovering the full potential of NAD+ by researching ChromaDex's Niagen® ingredient, patented nicotinamide riboside (NR), one of the most studied and...

read more
Skip to content